Biogen (BIIB) Offering Possible 18.34% Return Over the Next 14 Calendar Days

Biogen's most recent trend suggests a bullish bias. One trading opportunity on Biogen is a Bull Put Spread using a strike $225.00 short put and a strike $215.00 long put offers a potential 18.34% return on risk over the next 14 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $225.00 by expiration. The full premium credit of $1.55 would be kept by the premium seller. The risk of $8.45 would be incurred if the stock dropped below the $215.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Biogen is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Biogen is bullish.

The RSI indicator is at 21.42 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Biogen

3 Healthcare Stocks to Trade Now
Tue, 02 Apr 2019 15:58:14 +0000
On Monday, the equity markets started the quarter as strong as they ended the first one. The S&P 500 rose 1.2%, yet the healthcare sector was flattish red. It's a bit concerning to see a sector fall as the rest of the market rallies. So is it time to bail out on healthcare stocks?The answer is no, but it's more complicated than that because of the political risk. For as long as I can remember, healthcare stocks have been the target of political hate. Both Democrats and Republicans like beating up on these stocks while they use them for their soap boxes. This became very true during the 2016 elections when both sides of the drug companies became political footballs. Even now, the Republicans want to repeal Obamacare, and both sides want to gloat about crippling their pricing models. Either way, healthcare and drug companies are in the crosshairs.The overall macroeconomic environment still favors the long trade on Wall Street. But this sector has to swim upstream as it fights the added political current. It can do it but the approach is not as easy as finding good fundamentals to bet on. Going long healthcare stocks requires technical help and the positions should be as diverse as possible.InvestorPlace – Stock Market News, Stock Advice & Trading Tips * 10 Best ETFs for 2019: A Close Race at the Front But there are a few strong tickers within the healthcare sector that I would trade right here regardless of the extrinsic threats. Here are three to consider: Health Care Select Sector SPDR Fund (XLV)Source: Shutterstock First, I'd bet on a sector exchange-traded fund and there are many to choose from. At this stage, the Health Care Select Sector SPDR Fund (NYSEARCA:XLV) best represents the opportunity at hand. It is a basket of great companies proven for the long term. More importantly, and given all the geopolitical risk, the major tickers that make up the XLV pay a handsome dividend. This provides support if we were to have another market wide tizzy because of Brexit or the tariff wars.Furthermore, Johnson and Johnson (NYSE:JNJ), Pfizer (NYSE:PFE) and United Healthcare (NYSE:UNH), which are the top three holdings and comprise almost 25% of the ETF, have reasons to continue to their rallies. So buying the XLV is an easy way to bet on the whole sector without the risk of specific stock headlines. We recently saw what happened to Biogen (NASDAQ:BIIB) when they announced the failure of their Alzheimer drug. Johnson and Johnson (JNJ)Source: Shutterstock Late last year, Johnson and Johnson (NYSE:JNJ) had a headline scare and the stock fell 15% on the headline. They came under fire as they were accused of wrong doing with their Talcum baby powder product. The good news is that it is now clear that management didn't act maliciously. Mistakes happen and sometimes they have tragic consequences but the real problems are when the companies do evil things and this is not the case.Fundamentally, this is still a solid company with over 100 years of proven performance. It will take more than one incident to break it for good.The other saving grace was that when JNJ stock fell last year it did so from an all-time high. This would have been necessary regardless, so the Talc headline merely pushed the time table a bit. This doesn't diminish from the serious illnesses but from a stock perspective, investors over reacted on the headline and have since been clawing back their way.The opportunity in JNJ stock lies in the technicals. Since the drop to $121 per share, the stock has steadily recovered with a series of higher highs and higher lows. The $134 ledge was important for the bulls to retake as it is pivotal. * 7 ETFs to Buy for Serious Diversification Now JNJ stock is butting up against another potential resistance zone but it's also an opportunity. If the buyers can breakout of $140.60, then they can spike again to target the all-time highs once more. This would also close the Dec. 14 gap. This won't be easy and Johnson and Johnson stock will need the market in general to help. AbbVie (ABBV)Source: Shutterstock The AbbVie (NYSE:ABBV) stock cratered on its last earnings report. But its problems started in January 2018 and since then, ABBV stock is down 35% from the closing high.But therein lies the opportunity.The descent in ABBV has developed a sharp descending wedge that needs to resolve itself soon. This is an intense series of lower highs and lower lows that is forming a bottom. The outcome from here is usually a sharp reversal and the bounce carries huge potential. But conversely, if the bottoming process fails, then it would become yet another ledge for even lower lows.Since February, ABBV stock has had higher lows, which usually increase the odds that the bottom is in. But the bulls are running into a wall at the $81 per share zone. So they need a strong push into it so that they can fill the gap all the way to $86. This will be easier said than done but it is the technical opportunity here.Meanwhile, it is imperative that the bulls maintain footing below, so they need to hold $79 per share, or else they risk losing the momentum that they so desperately need to breach the band of resistance.Usually when a quality stock knocks on a roof so many times it increases the odds of breaking through at the slightest trigger. And the move that follows is usually exaggerated, so ABBV has a chance at some redemption.This, of course, is a tactical trade, so I would set hard stop-loss orders for an escape if the short-term support fails.The exact trigger for ABBV stock will be the next earnings report. The reaction to the last one was horrendous as the stock fell 15%. So this will be management's chance to redeem themselves and deliver results that exceed expectations. Looking back in recent history there are no back-to-back negative ABBV earnings reactions on the stock chart.Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him as @racernic on Twitter and Stocktwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks From Around the World That Beat U.S. Stocks * 7 Breakout Stocks to Watch in 2019 * 5 Cheap Small-Cap Stocks to Buy Compare Brokers The post 3 Healthcare Stocks to Trade Now appeared first on InvestorPlace.

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
Tue, 02 Apr 2019 14:10:02 +0000
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Celgene Gets Positive CHMP Nod for Revlimid Label Expansion
Mon, 01 Apr 2019 20:24:08 +0000
Celgene (CELG) receives positive CHMP opinion for label expansions of IMiD medications – Revlimid and Imnovid.

These are the 20 most valuable brands in Massachusetts
Mon, 01 Apr 2019 18:56:11 +0000
20 Massachusetts brands made the top 500 of Brand Value's rankings, and almost all of them saw their value increase from 2018 to 2019. Two notable exceptions? Biogen and General Electric. $BIIB $GE

3 High Earnings-Yield Stocks
Mon, 01 Apr 2019 17:46:26 +0000
Investors may want to screen for stocks that are doubling 20-year, high-quality market corporate bonds in terms of return because these stocks are likely to show impressive margins. Warning! GuruFocus has detected 5 Warning Signs with CEO. Further, these stocks have an inexpensive valuation according to the Peter Lynch chart and a high financial strength rating according to GuruFocus.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.